Go to main content

  1. Home
  2. Research and development of vaccines

Coalition for Epidemic Preparedness Innovations

Research and development of vaccines

Disclaimer: The data for this page has been produced from IATI data published by Coalition for Epidemic Preparedness Innovations. Please contact them (Show Email Address) if you have any questions about their data.

Programme Data Last Updated: 24/06/2022

IATI Identifier: NO-BRC-917687811-CEPI_02


CEPI’s vision is a world in which epidemics and pandemics are no longer a threat to humanity. Going into the strategic period from 2022-2026, termed “CEPI 2.0”, CEPI aims to raise the bar to develop and scale vaccines and other promising biologic countermeasures even faster. The R&D community has moved with unprecedented speed in response to COVID-19, developing biological interventions like vaccines and monoclonal antibodies in less than 12 months. While these achievements are historic, what the world needs to avert the consequences of future epidemics and pandemics are countermeasures developed even faster. CEPI’s mission is to accelerate the development of vaccines and other biologic countermeasures against epidemic and pandemic threats so they can be accessible to all people in need. CEPI believes safe and effective vaccine in 100 days from the moment that a pathogen is sequenced and/ or the need for a vaccine is recognised to initial availability for use should be the aspiration. Over the strategic period, CEPI aims to invest USD 3.5 billion across three overall strategic objectives:


1) PREPARE for known epidemic and pandemic threats: End the acute phase of the COVID-19 pandemic by ensuring equitable access to a portfolio of COVID-19 vaccines favourable for LMICs and validate enabling science programmes to accelerate COVID-19 vaccine candidate development. Accelerate the development of vaccines and other biologic countermeasures against known high- risk pathogens, continuing vaccine development towards licensure for priority pathogens with a clear unmet need where vaccines could have an impact. Reduce the risk of further coronavirus pandemics, using the acceleration in vaccine technologies and methods due to COVID-19 response, with the ultimate objective to develop a broadly protective Betacoronavirus vaccine. 2) TRANSFORM the response to the next novel threat: Using vaccine prototypes and platform innovations to give us a head-start on other novel threats. Investing and scaling critical enabling sciences to further accelerate rapid vaccine development. Investing in innovations to ensure vaccine manufacturing is cheaper, faster, and closer to an outbreak. 3) CONNECT to enhance and expand global collaboration: Secure financing for epidemic preparedness and response, connecting countries, industry, public & private sectors from all over the world, and global health partners to develop vaccines and build commitment to preparedness and access. Improve coordination among key stakeholders to enable system readiness, driving for collaboration and solutions which will enable a faster system-wide response. Promote equitable access principles as the foundation of any effective global response.

Status - Implementation More information about Programme status
Programme Spend More information about Programme funding
Implementing Organisation(s) More information about implementing organisation(s)
  • Affinivax, Inc.
  • Aga Khan University
  • Aurobindo
  • Aurum Institute
  • BERC Africa
  • Benin FORS
  • BioNet-Asia Co.,Ltd.
  • Clover Biopharmaceuticals
  • Colorado State University
  • Connected DMV
  • CureVac
  • Dalhousie Univesity
  • Defence Science and Technology Laboratory
  • Diosynvax Ltd
  • Dynavax
  • Emergent BioSolutions
  • Epicentre
  • FIND
  • Gritstone bio, Inc.
  • IDT biologica
  • Imperial College
  • Inovio Pharmaceuticals
  • Integrum
  • International AIDS Vaccine Initiative
  • International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b)
  • International Vaccines Institute
  • Janssen
  • Larissa
  • Medicines and Healthcare products Regulatory Agency (MHRA)
  • Medigen Vaccine Biologics Corp.
  • MigVax Ltd
  • NEC OncoImmunity AS
  • National Autonomous University of Mexico
  • Nexelis
  • Nigeria NCDC
  • Nuova Ompi S.r.l
  • P-95
  • PATH
  • Panacea Biotec
  • Public Health England
  • Public Health Vaccines
  • Robert Koch Institute
  • SK bioscience
  • Shanghai Zerun Biotechnology Co., Ltd.
  • Taskforce for Global Health
  • Technical University of Mombasa
  • Themis Bioscience
  • Tulane University
  • UK - Department of Health and Social Care (DHSC)
  • UNITE Global Parliamentarians Network
  • Universiti Malaya
  • University of Antwerpen
  • University of Hong Kong
  • University of North-Carolina
  • University of Oxford, The
  • University of Pittsburgh
  • University of Queensland
  • University of Tokyo
  • Université Gamal Abdel Nasser de Conakry
  • VBI Vaccines Inc.
  • Valneva
  • Vaxxinity, Inc.
  • Viroclinics Biosciences B.V
  • Wageningen University & Research - Stichting Wageningen Research
  • Wellcome LEAP
  • Zalgen Labs

This site uses cookies

We use Google Analytics to measure how you use the website so we can improve it based on user needs. Google Analytics sets cookies that store anonymised information about how you got to the site, the internal pages you visit, how long you spend on each page and what you click on while you're visiting the site. Read more